Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Inserm (Institut National De La Santé Et De La Recherche Medicale) has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner. The prosecution is focused within 1 distinct art unit. This indicates a very specific technical review for the 1 pending office action.
The busiest examiner for the company is COOK, LISA V. This individual is responsible for 1 busiest examiner pending office action. This single action accounts for the entire 1 pending office action currently active for the company. Because there is only 1 distinct examiner involved, the company's current success in the Biotechnology & Pharmaceuticals area depends on the findings of COOK, LISA V. The presence of 1 distinct art unit indicates a centralized examination process for this single matter.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §103 only | 1 (14%) |
| §112 only | 2 (29%) |
| Multi-statute (no §101) | 3 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STONEBRAKER, ALYSSA RAE | 1 | 58.3% | +49.2% |
| HUMPHRIES, NICHOLAS ADAM | 1 | 36.1% | +75.9% |
| ALDARRAJI, ZAINAB MOHAMMED | 1 | 66.7% | +18.7% |
| FARAG, AMAL ALY | 1 | 68.7% | +36.8% |
| GRASER, JENNIFER E | 1 | 76.7% | +23.4% |
| KIM, TAEYOON | 1 | 51.5% | +52.1% |
| SALMON, KATHERINE D | 1 | 42.8% | +37.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18255885 | MICRO-DEVICE TRACKING AND VIZUALISATION SYSTEM | FARAG, AMAL ALY | 78d overdue |
| 17422737 | AAV-MEDIATED GENE THERAPY RESTORING THE OTOFERLIN GENE | KIM, TAEYOON | 15d overdue |
| 18551385 | EX-VIVO PROLIFERATION OF HUMAN PHAGOCYTIC CELLS | HUMPHRIES, NICHOLAS ADAM | — |
| 18248120 | COMBINATION OF INHALED ANTIBODIES AND IMMUNOMODULATORY AGENTS FOR THE TREATMENT OR PREVENTION OF RESPIRATORY INFECTIONS | GRASER, JENNIFER E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18255885 | MICRO-DEVICE TRACKING AND VIZUALISATION SYSTEM | FARAG, AMAL ALY | 78d overdue |
| 17422737 | AAV-MEDIATED GENE THERAPY RESTORING THE OTOFERLIN GENE | KIM, TAEYOON | 15d overdue |
| 18256706 | ULTRASOUND DEVICE TRACKING SYSTEM | ALDARRAJI, ZAINAB MOHAMMED | 8d overdue |
| 18692037 | ANTI-HUMAN CD45RC BINDING DOMAINS AND USES THEREOF | STONEBRAKER, ALYSSA RAE | — |
| 18551385 | EX-VIVO PROLIFERATION OF HUMAN PHAGOCYTIC CELLS | HUMPHRIES, NICHOLAS ADAM | — |
| 18248120 | COMBINATION OF INHALED ANTIBODIES AND IMMUNOMODULATORY AGENTS FOR THE TREATMENT OR PREVENTION OF RESPIRATORY INFECTIONS | GRASER, JENNIFER E | — |
| 16633183 | NEW SUBPOPULATIONS OF CANCER ASSOCIATED FIBROBLASTS AS PROGNOSIS MARKERS FOR IMMUNOTHERAPY TREATMENTS | SALMON, KATHERINE D | — |
| Art Unit | Apps |
|---|---|
| 1631 | 2 |
| 3797 | 1 |
| 3798 | 1 |
| 1645 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18692037 | ANTI-HUMAN CD45RC BINDING DOMAINS AND USES THEREOF | STONEBRAKER, ALYSSA RAE | — | §112 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18551385 | EX-VIVO PROLIFERATION OF HUMAN PHAGOCYTIC CELLS | HUMPHRIES, NICHOLAS ADAM | 1631 | §102§103 | Non-Final OA | — | Pending | Sep 19, 2023 |
| 18256706 | ULTRASOUND DEVICE TRACKING SYSTEM | ALDARRAJI, ZAINAB MOHAMMED | 3797 | §103 | Final Rejection | 8d overdue | Pending | Jun 09, 2023 |
| 18255885 | MICRO-DEVICE TRACKING AND VIZUALISATION SYSTEM | FARAG, AMAL ALY | 3798 | §101§103 | Non-Final OA | 78d overdue | Pending | Jun 05, 2023 |
| 18248120 | COMBINATION OF INHALED ANTIBODIES AND IMMUNOMODULATORY AGENTS FOR THE TREATMENT OR PREVENTION OF RESPIRATORY INFECTIONS | GRASER, JENNIFER E | 1645 | §102§103§112 | Non-Final OA | — | Pending | Apr 06, 2023 |
| 17422737 | AAV-MEDIATED GENE THERAPY RESTORING THE OTOFERLIN GENE | KIM, TAEYOON | 1631 | §102§103 | Final Rejection | 15d overdue | Pending | Jul 13, 2021 |
| 16633183 | NEW SUBPOPULATIONS OF CANCER ASSOCIATED FIBROBLASTS AS PROGNOSIS MARKERS FOR IMMUNOTHERAPY TREATMENTS | SALMON, KATHERINE D | 1682 | §112 | Non-Final OA | — | Pending | Jan 23, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial